CAAR T-cell therapy offers a more targeted route for neurological autoimmune diseases

Researchers at DZNE and Charité—Universitätsmedizin Berlin are working on a targeted therapy for neurological autoimmune diseases. So far, they have successfully tested their approach in mouse studies involving two such conditions. Their concept is based on deliberately modified immune cells, so-called CAAR T cells, designed to eliminate only the immune cells responsible for causing disease.

≈